Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
NCT06356584Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, fruquintinib in colorectal cancer (CRC), sponsored by Shandong Cancer Hospital. Started Apr 2024; status: recruiting.
02
Drugs
sintilimabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06356584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356584.